LUNG Valuation

Pulmonx Corp

Add to Watchlist

Advanced Chart

5.250

+0.040(+0.770%)

Overview
Forecast
Valuation

LUNG Relative Valuation

LUNG's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, LUNG is overvalued; if below, it's undervalued.

Historical Valuation

Pulmonx Corp (LUNG) is now in the Fair zone, suggesting that its current forward PS ratio of 2.14 is considered Fairly compared with the five-year average of 13.41. The fair price of Pulmonx Corp (LUNG) is between 2.33 to 52.10 according to relative valuation methord.

Relative Value

Fair Zone

2.33-52.10

Current Price：5.25

Fair

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

2.43

P/B

Median3y

3.10

Median5y

3.96

-15.91

FCF Yield

Median3y

-11.06

Median5y

-8.20

Competitors Valuation Multiple

The average P/S ratio for LUNG's competitors is 1.55, providing a benchmark for relative valuation. Pulmonx Corp Corp (LUNG) exhibits a P/S ratio of 2.14, which is 38.21% above the industry average. Given its robust revenue growth of 23.28%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap